COVID-19 Pediatric Vaccine Hesitancy among Racially Diverse Parents in the United States

On 29 October 2021, the U.S. FDA authorized the Pfizer-BioNTech COVID-19 (SARS-CoV-2) vaccine for emergency use in children ages 5–11 years. Racial/ethnic minorities have born the greatest burden of pediatric COVID-19 infection and hospitalization. Research indicates high prevalence of parental vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fisher, Celia B., Gray, Aaliyah, Sheck, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778198/
https://www.ncbi.nlm.nih.gov/pubmed/35062692
http://dx.doi.org/10.3390/vaccines10010031

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778198/
https://www.ncbi.nlm.nih.gov/pubmed/35062692
http://dx.doi.org/10.3390/vaccines10010031

Ejemplares similares